The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of homologous recombination repair (HRR) or nucleotide excision repair (NER) deficiency on sensitivity to antibody drug conjugate (ADC) payloads in urothelial cancer.
 
Surish P Shanmugam
No Relationships to Disclose
 
Yuzhen Zhou
No Relationships to Disclose
 
Vincent D'Andrea
No Relationships to Disclose
 
Timothy Hanlon
No Relationships to Disclose
 
Raie Bekele
No Relationships to Disclose
 
Zoltan Szallasi
Patents, Royalties, Other Intellectual Property - co-inventor on a patent used in the myChoice HRD assay
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Kent William Mouw
Stock and Other Ownership Interests - Riva Therapeutics
Honoraria - OncLive/MJH Life Sciences; UpToDate
Consulting or Advisory Role - Riva Therapeutics; Urogen pharma
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Institutional patent filed on mutational signatures of DNA repair deficiency